Format

Send to

Choose Destination
See comment in PubMed Commons below
J Natl Cancer Inst. 2014 Apr;106(4):dju029. doi: 10.1093/jnci/dju029. Epub 2014 Mar 13.

Better therapeutic trials in ovarian cancer.

Author information

1
Affiliations of authors: University of Arizona Cancer Center, Tucson, AZ (MAB); Department of Pathology and Laboratory Medicine, Vancouver General Hospital, Vancouver, BC, Canada (CBG); Molecular Signalling Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD (ECK); Director, Policy and Advocacy, Prevent Cancer Foundation, Alexandria, VA (KOK); Pathology and Laboratory Medicine (DH) and Department of Medical Oncology (KDS), University of British Columbia, Vancouver, BC, Canada (DH); Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY (CA); Department of Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, MA (MJB); CR UK/UCL Cancer Trials Centre, University College London Cancer Institute, London, UK (JAL); Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada (AMO).

Abstract

The Ovarian Task Force of the Gynecologic Cancer Steering Committee convened a clinical trials planning meeting on October 28-29, 2011, with the goals to identify key tumor types, associated molecular pathways, and biomarkers for targeted drug intervention; review strategies to improve early-phase screening, therapeutic evaluation, and comparison of new agents; and optimize design of randomized trials in response to an evolving landscape of scientific, regulatory, and funding priorities. The meeting was attended by international clinical and translational investigators, pharmaceutical industry representatives, government regulators, and patient advocates. Panel discussions focused on disease types, early-phase trials, and randomized trials. A manuscript team summarized the discussions and assisted with formulating key recommendations. A more integrated and efficient approach for screening new agents using smaller selective randomized trials in specific disease-type settings was endorsed, together with collaborative funding models between industry and the evolving national clinical trials network, as well as efforts to enhance public awareness and study enrollment through advocacy.

PMID:
24627272
PMCID:
PMC3982885
DOI:
10.1093/jnci/dju029
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems Icon for PubMed Central
    Loading ...
    Support Center